/
OMER
$9.91+$1.24 (+14.30%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$627.5M
72M shares
52-week range
$2.95 – $17.65
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.82%
Moderate
Price (6 mo)
Loading chart…
Change$-5.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.9M | $111.8M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $512.0K | $2.7M | $1.6M | $1.4M | $0 | $0 | $0 | $0 |
| Gross profit | $29.4M | $109.2M | −$1.6M | −$1.4M | $0 | $0 | $0 | $0 |
| Gross margin | 98.3% | 97.6% | — | — | — | — | — | — |
| R&D | $89.9M | $109.7M | $107.6M | $118.8M | $112.7M | $114.9M | $119.5M | $81.3M |
| Operating income | −$112.2M | −$63.4M | −$156.9M | −$173.6M | −$163.4M | −$164.5M | −$169.3M | −$122.8M |
| EBITDA | −$122.5M | −$60.0M | −$168.0M | −$170.5M | −$158.4M | −$143.2M | −$157.0M | −$1.8M |
| Net income | −$126.8M | −$84.5M | −$138.1M | −$111.4M | $47.4M | −$117.8M | −$156.8M | −$3.4M |
| Net margin | -424.4% | -75.6% | — | — | — | — | — | — |
| EPS (diluted) | -2.61 | -2.16 | -2.41 | 3.12 | 0.46 | -1.88 | -2.70 | -0.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $68M | $0.05 | $0.04–$0.06 | 1 |
| 2027 | $143M | $-0.28 | $-0.32–$-0.25 | 1 |
| 2028 | $265M | $0.90 | $0.83–$0.98 | 2 |
| 2029 | $397M | $1.76 | $1.58–$2.03 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
www.omeros.com- Employees
- 175
- IPO / List date
- Oct 8, 2009
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds OMER.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 344,500 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OMER yet.
